ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,306.04
      0.02%
      US Tech 100
      18,387.60
      0.38%
      Dow Jones
      38,852.86
      -0.55%
      Brent Oil
      84.205
      -0.14%
      Bitcoin
      68,321.00
      0.04%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Genprex Inc (GNPX)

      7. Genprex Inc (GNPX) News

      GNPX

      Genprex (GNPX)

      Genprex Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GNPX
      DateTimeSourceHeadlineSymbolCompany
      05/20/20244:35PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
      05/15/20244:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
      05/14/20248:31AMPR Newswire (US)Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
      05/13/20248:31AMPR Newswire (US)Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsNASDAQ:GNPXGenprex Inc
      05/09/20248:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
      05/08/20246:08PMPR Newswire (US)Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerNASDAQ:GNPXGenprex Inc
      05/01/20248:31AMPR Newswire (US)Genprex to Present and Participate at Upcoming May Investor and Industry ConferencesNASDAQ:GNPXGenprex Inc
      04/09/20248:31AMPR Newswire (US)Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
      04/03/20248:31AMPR Newswire (US)Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
      04/02/20248:31AMPR Newswire (US)Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemNASDAQ:GNPXGenprex Inc
      03/22/20244:10PMPR Newswire (US)Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
      03/19/20241:24PMPR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
      03/19/20248:36AMPR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
      03/12/20249:01AMPR Newswire (US)Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersNASDAQ:GNPXGenprex Inc
      03/06/20249:18AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
      03/06/20248:30AMPR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
      02/26/20248:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
      02/21/20244:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
      02/21/20244:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
      02/21/20244:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
      02/14/20242:14PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNPXGenprex Inc
      02/07/20248:15AMPR Newswire (US)Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsNASDAQ:GNPXGenprex Inc
      02/06/20247:30AMPR Newswire (US)Genprex to Present at Upcoming BIO CEO & Investor ConferenceNASDAQ:GNPXGenprex Inc
      02/05/20248:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
      02/05/20247:30AMPR Newswire (US)Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
      02/02/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
      01/31/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
      01/31/20248:42AMPR Newswire (US)Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024NASDAQ:GNPXGenprex Inc
      01/05/20244:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
      01/05/20247:00AMPR Newswire (US)Genprex Provides Business Update and Outlook for 2024NASDAQ:GNPXGenprex Inc
       Showing the most relevant articles for your search:NASDAQ:GNPX

      Your Recent History

      BOV
      SNEC34M
      Sony
      Delayed Upgrade Clock